BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Lin TJ, Lee HC, Lin CL, Wang CK, Chen KY, Wu DC. CYP2C19 polymorphism has no influence on rabeprazole-based hybrid therapy for Helicobacter pylori eradication. World J Clin Cases 2018; 6(12): 514-520 [PMID: 30397607 DOI: 10.12998/wjcc.v6.i12.514]
URL: https://www.wjgnet.com/2150-5330/full/v6/i12/514.htm
Number Citing Articles
1
Azucena Arévalo Galvis, Alba Alicia Trespalacios Rangel, William Otero Regino. Personalized therapy for Helicobacter pylori : CYP2C19 genotype effect on first‐line triple therapy Helicobacter 2019; 24(3): e12574 doi: 10.1111/hel.12574
2
Juan Fu, Chang-Feng Sun, Hong-Yan He, Suvash Chandra Ojha, Han Shi, Cun-Liang Deng, Yun-Jian Sheng. The effect of CYP2C19 gene polymorphism on the eradication rate of Helicobacter pylori by proton pump inhibitors-containing regimens in Asian populations: a meta-analysisPharmacogenomics 2021; 22(13): 859 doi: 10.2217/pgs-2020-0127
3
He-Jian Zhang, Xue-Hui Zhang, Jie Liu, Lu-Ning Sun, Yi-Wen Shen, Chen Zhou, Hong-Wen Zhang, Li-Jun Xie, Juan Chen, Yun Liu, Yong-Qing Wang. Effects of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of proton pump inhibitorsPharmacological Research 2020; 152: 104606 doi: 10.1016/j.phrs.2019.104606
4
Wen Gao, Hui Ye, Xin Deng, Chi Wang, Ying Xu, Yixuan Li, Xuezhi Zhang, Hong Cheng. Rabeprazole‐amoxicillin dual therapy as first‐line treatment for H pylori eradication in special patients: A retrospective, real‐life study Helicobacter 2020; 25(5) doi: 10.1111/hel.12717